Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
The way researchers and clinicians talk about Alzheimer’s treatments is changing. Instead of “disease-modifying therapies,” the field now uses “disease-targeted therapies” or DTTs—a shift that reflects a more honest understanding of what these medicines actually do. Alongside this terminology update, the medical community has adopted the CADRO classification system (Common Alzheimer’s Disease Research Ontology), which organizes treatments by their biological mechanism rather than making promises about outcomes. This matters because it helps patients, caregivers, and doctors understand exactly how a drug is supposed to work: by targeting amyloid-beta buildup, tau tangles, inflammation, or other specific pathways in the brain.
The timing of these classification updates is significant. In 2026, the FDA approved ALPHA-1062 (Zunveyl), a new-generation acetylcholinesterase inhibitor for mild-to-moderate Alzheimer’s disease—the first oral treatment of its kind approved in over a decade. Meanwhile, AXS-05, designed to address agitation that affects up to 76% of Alzheimer’s patients, is awaiting FDA decision on April 30, 2026. These approvals and pending decisions have pushed the field to clarify how drugs are categorized, since the landscape of Alzheimer’s treatments is becoming more complex and more specific about what each medication targets.
Table of Contents
- Why Drug Classification Systems Matter in Alzheimer’s Care
- New Treatments and How the Classification System Clarifies Them
- Emerging Treatments for Behavioral Symptoms and Agitation
- At-Home Options and What They Mean for Treatment Access
- Limitations and Risks in the Newer Treatment Era
- How CADRO Classification Helps Researchers and Developers
- The Emerging Treatment Landscape and What’s Next
- Conclusion
Why Drug Classification Systems Matter in Alzheimer’s Care
A classification system isn’t just academic language—it determines how doctors prescribe treatments and how patients understand their options. The old framework of “disease-modifying therapy” implied that a drug would slow, stop, or reverse Alzheimer’s disease itself. CADRO’s new approach is more precise. It categorizes drugs by their mechanism: amyloid-beta targeting, tau targeting, APOE and lipid pathways, transmitter receptors, neuroinflammation, oxidative stress, and metabolism. This means a patient reading their treatment options immediately understands whether a drug attacks the plaques believed to damage neurons, addresses inflammatory responses in the brain, or restores neurotransmitter function.
The shift from DMT to DTT language acknowledges that we don’t yet have a cure. Anti-amyloid antibodies like Leqembi and Kisunla reduce cognitive decline by 25 to 35%—which is meaningful but not a reversal of disease. Calling them “disease-targeted” rather than “disease-modifying” sets appropriate expectations. This distinction matters for patient decision-making, especially when someone faces regular intravenous infusions, monitoring for potential brain microhemorrhages, and out-of-pocket costs. The honest terminology helps families weigh benefits against burdens more clearly.
New Treatments and How the Classification System Clarifies Them
ALPHA-1062 (Zunveyl) represents a specific type of drug that fits cleanly into the CADRO system—it targets neurotransmitter receptors. As an acetylcholinesterase inhibitor, it works by preserving acetylcholine in the brain, supporting communication between remaining neurons. This isn’t a new mechanism; drugs like donepezil and rivastigmine have worked this way for years. What’s new is the formulation. ALPHA-1062 uses a prodrug approach with improved bioavailability and reduced gastrointestinal side effects—a meaningful advancement for patients who previously experienced nausea or vomiting on older acetylcholinesterase inhibitors.
However, this drug still does not halt disease progression; it may ease cognitive symptoms in early disease stages, but only the anti-amyloid antibodies have demonstrated ability to slow actual cognitive decline. The challenge with expanded treatment options is that patients and families need clear guidance on what each drug does and what it doesn’t. ALPHA-1062 works best for mild-to-moderate disease and addresses symptoms. Leqembi or Kisunla address underlying pathology earlier in disease course. AXS-05, awaiting FDA approval, fills a different gap entirely—it addresses the behavioral crisis of agitation, which is a primary driver of nursing home placement. These are complementary, not interchangeable approaches, and the CADRO classification helps patients understand which category their prescribed drug falls into.
Emerging Treatments for Behavioral Symptoms and Agitation
Agitation in Alzheimer’s disease is severe and widespread. Up to 76% of patients experience agitation—aggressive outbursts, restlessness, or verbal hostility—making it a crisis point for family caregivers and one of the leading reasons families seek nursing home placement. Until recently, treating agitation meant reaching for antipsychotics, sedating medications that come with their own serious risks in older adults, including increased stroke risk and mortality in elderly patients with dementia. AXS-05 offers a different approach.
The drug combines dextromethorphan and bupropion in a fixed-dose combination designed specifically for Alzheimer’s disease agitation. In trials, the combination showed efficacy that drove the FDA to grant it Priority Review status, with a decision expected April 30, 2026. This medication doesn’t sedate; instead, it modulates neurotransmitter pathways in ways that reduce agitation without the blanket cognitive dulling of antipsychotics. The CADRO system would classify this in the transmitter receptor category, making it clear that it’s a targeted approach rather than a chemical restraint.
At-Home Options and What They Mean for Treatment Access
One barrier to using newer Alzheimer’s treatments is the clinical burden. Anti-amyloid antibodies like Leqembi require regular intravenous infusions—typically every four weeks—plus periodic brain MRIs to monitor for amyloid-related imaging abnormalities (ARIA), a potential side effect that can cause brain microhemorrhages or microinfarcts. This clinical overhead means missed appointments, travel, and the stress of sitting in an infusion center, which can be difficult for people with advanced cognitive decline. The FDA approval of Leqembi’s at-home injectable form addresses this barrier.
Patients can now self-administer or receive injections at home, reducing the need for repeated clinic visits. The FDA is expected to make a decision in May 2026 on approving starter doses for home use, which would further streamline treatment initiation. This shift matters because it expands access—rural patients no longer need to travel hours for infusions, and people with limited mobility or anxiety about clinical settings become eligible candidates. However, at-home administration creates new responsibilities for patient or caregiver competency with injections and for monitoring side effects at home rather than in a clinical setting.
Limitations and Risks in the Newer Treatment Era
The expansion of Alzheimer’s treatment options brings benefits but also risks and limitations that patients must understand. Anti-amyloid antibodies require APOE4 genotyping and close monitoring for ARIA. These drugs are only approved for mild cognitive impairment or mild dementia stages; they do not work in moderate or advanced disease. This limits who can benefit and creates a window where treatment must start before significant cognitive damage occurs.
Similarly, while ALPHA-1062 offers better tolerability than older acetylcholinesterase inhibitors, it still works best for mild-to-moderate disease and does not slow underlying neurodegeneration. Patients sometimes develop false hope that newer approvals mean a cure is near; clearer classification language helps counter this, but clinicians must still have direct conversations about what these drugs do and don’t do. The cost barrier remains significant. Anti-amyloid antibodies can exceed $25,000 annually, putting them out of reach for many uninsured or underinsured patients despite FDA approval.
How CADRO Classification Helps Researchers and Developers
The adoption of the CADRO classification system isn’t just helpful for patients and doctors—it transforms how researchers prioritize development. By organizing treatments into eight mechanistic categories (amyloid-beta, tau, APOE/lipids, transmitter receptors, neuroinflammation, oxidative stress, metabolism, and others), the system makes gaps visible. Researchers can see where multiple drugs target the same pathway and where entire pathways remain untreated. This data-driven approach accelerates innovation in underdeveloped categories.
For example, neuroinflammation is an active research area with several candidates in clinical trials but no FDA-approved drugs yet. Oxidative stress pathways remain largely unexplored in Alzheimer’s treatment. The CADRO framework helps funders, companies, and regulators allocate resources strategically rather than allowing redundancy or neglect of promising targets. It also standardizes how treatment mechanisms are discussed across research papers, making it easier for clinicians to translate complex trial results into clinical decision-making.
The Emerging Treatment Landscape and What’s Next
The years 2023 through 2026 represent a historic shift for Alzheimer’s treatment. For decades, the field had only symptomatic treatments—acetylcholinesterase inhibitors and memantine—that provided modest cognitive benefit without touching disease pathology. Now, anti-amyloid antibodies offer the first medicines that alter disease progression, and the pipeline includes candidates targeting tau tangles, neuroinflammation, metabolic dysfunction, and other mechanisms. AXS-05’s impending approval adds behavioral crisis management to that arsenal.
The next frontier will likely involve combination therapy—using drugs from different CADRO categories simultaneously to attack multiple disease pathways. Research is already exploring whether an anti-amyloid agent plus a tau-targeting drug plus a neuroinflammatory agent might work better than any single drug alone. This will require even more sophisticated classification and clearer communication about drug interactions and safety profiles. The field is moving toward personalized medicine where APOE4 status, biomarker profiles, and stage of disease guide specific drug selection—making accurate, transparent classification systems not just helpful but essential to good care.
Conclusion
The updated drug classification system—shifting from “disease-modifying therapy” to “disease-targeted therapy” and adopting the CADRO mechanistic framework—reflects a maturation in how the field understands Alzheimer’s treatment. These changes make drug options more transparent and help patients, families, and doctors make informed decisions. With new approvals like ALPHA-1062, pending decisions on AXS-05, and expanded access options like at-home Leqembi administration, the landscape of available treatments is broader than ever. However, availability doesn’t mean universality.
These drugs work best in early disease stages, carry real risks and limitations, and remain unaffordable for many. The honest terminology of DTTs—rather than the aspirational promise of DMTs—creates space for realistic conversations about what treatment can and cannot do. If you or a loved one is facing an Alzheimer’s diagnosis, discussing these options with a neurologist or cognitive specialist who understands both the CADRO classification system and your individual circumstances is the next step. The goal isn’t cure; it’s slowing decline, managing symptoms, and maintaining quality of life as long as possible.
